ImCheck Provides Promising Updated Patient Response Data from the Phase I/IIa EVICTION Trial with…
Oral presentation includes positive safety data across a wide range of ICT01 doses and efficacy data from patients receiving ICT01 plus pembrolizumab confirming durable clinical responses at low ICT01 dosesOne patient with…